Clinical trial
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
NCT00493467 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00493467 |
|---|---|
| Title | Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas |
| Official title | Phase II Study of Zevalin for the Treatment of Early-Stage Indolent Lymphomas |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Biogen Industry CTI BioPharma |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Ibritumomab Tiuxetan (Zevalin), Rituximab |
| Enrollment | 31 |
| Start date | Jun 1, 2006 |
| Primary completion | Apr 1, 2015 |
| Completion | Aug 11, 2022 |
| First posted | Jun 28, 2007 |
| Last update posted | Sep 15, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: